Chapter 42 — Further Reading

A note on this list. This chapter's subject is a structure, and the best sources on it are mostly not about peptides. They are about conflict of interest, advertising regulation, attention markets, and the sociology of how claims travel. Read them that way and they transfer to the next drug class without modification.

A second note, and it is the chapter applied to itself. Every source below has a business model. Regulatory guidance is written by an agency with an institutional interest in the legitimacy of its own remit. Academic work is produced by people whose careers reward publishable findings. Trade journalism is funded by advertising. Books are sold. None of that makes any of them wrong; all of it tells you where to check first. Run the five-question read on this reading list.

Tier 1 — Start here

This book, first. Chapter 6 (how claims degrade as they travel — this chapter is its commercial counterpart), Chapter 12 (the pharmacology, legal basis, and safety record of compounded preparations, which Case Study 1 assumes), Chapter 19 (the unregulated supply chain), and Chapter 38 (the regulatory architecture, which §42.7 samples rather than duplicates).

Federal Trade Commission, "Disclosures 101 for Social Media Influencers" (FTC, 2019, updated subsequently). Short, plainly written, free, and the single most useful practical document on this subject. It is written for creators, which is why it is so instructive for audiences: it tells you exactly what a compliant disclosure looks like, and therefore what a non-compliant one looks like.

Federal Trade Commission, "Guides Concerning the Use of Endorsements and Testimonials in Advertising" (16 CFR Part 255; substantially revised 2023). The underlying rules. Read the sections on material connections and on consumer reviews. Note how much of it addresses the relationship rather than the claim — that division is §42.7's thesis in legal form.

U.S. Food and Drug Administration, Office of Prescription Drug Promotion — consumer-facing "Drug Advertising" material and the public archive of untitled and warning letters. The letters are the best hour on this list. Each one describes, specifically, a promotional claim that crossed a line and why. Reading five of them gives you a working intuition for what "fair balance" means in practice, and Case Study 2 becomes concrete.

World Health Organization, "Ethical Criteria for Medicinal Drug Promotion" (WHO, 1988). Old, short, and still the clearest statement of the international consensus position that Case Study 2 §1 describes — the one under which consumer advertising of prescription medicines is simply not done.

Tier 2 — The research

On conflict of interest and why disclosure underperforms

Cain DM, Loewenstein G, Moore DA. "The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest." Journal of Legal Studies 34(1), 2005. The founding experimental result behind §42.3's counterintuitive paragraph. Advisors who disclosed gave more biased advice; recipients did not discount enough.

Loewenstein G, Sah S, Cain DM. "The Unintended Consequences of Conflict of Interest Disclosure." JAMA 307(7), 2012. A short, medically framed summary of the same literature. Start here if you read only one item in this subsection.

Sah S, Loewenstein G, Cain DM. "The Burden of Disclosure: Increased Compliance with Distrusted Advice." Journal of Personality and Social Psychology 104(2), 2013. The mechanism: refusing advice after someone has been candid with you feels like an accusation, so people comply against their own judgment. This is the paper that should end any expectation that disclosure is self-evidently protective.

Institute of Medicine (Lo B, Field MJ, eds.). Conflict of Interest in Medical Research, Education, and Practice. National Academies Press, 2009. The comprehensive institutional treatment. Long; read the summary and the chapter on practice.

DeJong C, Aguilar T, Tseng C-W, et al. "Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Part D." JAMA Internal Medicine 176(8), 2016. Why gradients do not need to be steep to move outcomes at scale. Observational, so read the limitations, but the direction and consistency are hard to explain away.

On advertising and medical marketing

Schwartz LM, Woloshin S. "Medical Marketing in the United States, 1997–2016." JAMA 321(1), 2019. The best single empirical overview of where marketing money goes in medicine and how the mix has shifted. Descriptive rather than causal, which is exactly what makes it useful.

Ventola CL. "Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?" P&T 36(10), 2011. A fair-minded review of both sides of the argument in Case Study 2 §5. Somewhat dated on spending figures; the structure of the debate has not changed.

On how content travels

Vosoughi S, Roy D, Aral S. "The Spread of True and False News Online." Science 359(6380), 2018. The study discussed in the chapter's 🔬 Read the Study callout. Read it with that callout's population-and-endpoint warning in hand: the corpus is predominantly political rumor, the endpoint is diffusion rather than belief or behavior, and applying it to health content is an inference by structural analogy rather than a finding.

Lazer DMJ, Baum MA, Benkler Y, et al. "The Science of Fake News." Science 359(6380), 2018. The companion review. Useful precisely because it is careful about how little is established.

Chou W-YS, Oh A, Klein WMP. "Addressing Health-Related Misinformation on Social Media." JAMA 320(23), 2018. Short, health-specific, and honest about the limits of the intervention literature.

Tier 3 — Going deeper

Wu T. The Attention Merchants: The Epic Scramble to Get Inside Our Heads. Knopf, 2016. The history of the business model. If you want to understand why §42.4 and §42.5 describe an economic law rather than a recent failure of character, this is the book.

Zuboff S. The Age of Surveillance Capitalism. PublicAffairs, 2019. Long, contested, and worth arguing with. Read it as a strong thesis to be tested rather than a settled account — which is, after all, this book's standing instruction.

Brody H. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Rowman & Littlefield, 2007. The ethical analysis of the physician-industry relationship that underlies §42.6. Written by a physician, and unusually free of both defensiveness and outrage.

Elliott C. White Coat, Black Hat: Adventures on the Dark Side of Medicine. Beacon Press, 2010. On the commercialization of medical authority. Read §42.6's credential problem first, then this.

Goldacre B. Bad Pharma. Fourth Estate, 2012. Principally about publication bias and missing trials, which is the selection effect of §42.3 operating on the scientific literature rather than on content. Reading the two together is the point: the same mechanism, two very different institutions.

Gigerenzer G. Risk Savvy: How to Make Good Decisions. Viking, 2014. On how risk information is presented and misunderstood — the necessary companion to any discussion of "fair balance."

Federal Trade Commission, "Health Products Compliance Guidance" (FTC, December 2022). The substantiation standard for health claims in advertising, in detail. Technical, but it answers the question "what evidence would a seller legally need for that claim?" — which is a question worth being able to answer.

If you only do one thing

Read the FTC's "Disclosures 101 for Social Media Influencers" — it takes twenty minutes — and then run the five-question read from §42.9 on the next three pieces of health content you encounter.

Make one of the three a piece of content you agree with. That one is the exercise. The other two are practice.